TrialBone marrow transplantation2019

A phase IV, randomized, multicenter, open-label trial comparing efficacy and systemic exposure for a standard weight-based dose versus a fixed dose of plerixafor in combination with G-CSF in patients with Non-Hodgkin's lymphoma weighing ≤70 kg.

John Kuruvilla et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.